Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Stem cell inhibitor

DRUG CLASS:

Stem cell inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	GZ17-6.02 Sensitive: D – Preclinical GZ17-6.02 Sensitive : D	GZ17-6.02 Sensitive: D – Preclinical GZ17-6.02 Sensitive : D
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	GZ17-6.02 Sensitive: D – Preclinical GZ17-6.02 Sensitive : D	GZ17-6.02 Sensitive: D – Preclinical GZ17-6.02 Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	palbociclib + GZ17-6.02 Sensitive: D – Preclinical palbociclib + GZ17-6.02 Sensitive : D	palbociclib + GZ17-6.02 Sensitive: D – Preclinical palbociclib + GZ17-6.02 Sensitive : D